Informed Prostate Cancer Patient Support

Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer - ScienceDirect sciencedirect.com Patient-reported Outcomes from a Phase III Randomized Controlled Trial Exploring Optimal Sequencing of Short-term Androgen Deprivation Therapy with Prostate Radiotherapy in Localized Prostate Cancer 3-4 minutes *Presented in part at the Genitourinary Cancers Symposium 2020, San Francisco, California (Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 315-315) ABSTRACT Background Two phase III randomized controlled trials (xxxx, RTOG-9413) and a meta-analysis have shown an impact of sequencing of androgen deprivation therapy (ADT) and radiotherapy on oncologic outcomes in prostate cancer (PCa). However, the impact of sequencing strategy on heal

Pre-existing cell subpopulations in primary prostate cancers display surface fingerprint of docetaxel-resistant cells | bioRxiv

Prostatepedia Digest 1.26.2021

Prostate cancer treatment: strategies for managing side effects kevinmd.com Prostate cancer treatment: strategies for managing side effects Miles J. Varn, MD 5-6 minutes After skin cancer, prostate cancer is the most common cancer diagnosed in men in the U.S., with one in eight men at risk of being diagnosed with this cancer during his lifetime. If you or a man you care about is undergoing prostate cancer treatment, you may be living with treatment-related side effects. These can vary depending on the type of treatment, including hormone therapy, radiation, surgery, immunotherapy, cryotherapy, and chemotherapy. Some of the most common side effects include incontinence, erectile dysfunction, infertility, and fatigue. The good news is that there are approaches that can help you manage and mitigate these side effects in most cases. Managing incontinence Men may face several types of in

The Early Stages of Research on Targeting MYC in Prostate Cancer Dean Felsher, MD, PhD, of Stanford Medicine discusses the importance of developing a therapy to target MYC alterations in men with prostate cancer. An unmet medical need in the field is understanding which patients will respond to immunotherapy. In the near future, Felsher believes that further exploration of MYC-targeted therapy will answer the question of why some patients respond to immunotherapy while other do not. Thus far, the impact of MYC-related clinical trial research has been limited in the prostate cancer space, explains Felsher. However, he believes that the short term effects will pay off in long term. Another short-term effect of studying the MYC gene is aid in the development of new agents or new approaches. Currently, no drug directly targets MYC.  

MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1 | eLife elifesciences.org MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1 Tessa M Popay, Jing Wang, Clare M Adams, Gregory Caleb Howard, Simona G Codreanu, Stacy D Sherrod, John A McLean, Lance R Thomas, Shelly L Lorey, Yuichi J Machida, April M Weissmiller, Christine M Eischen, Qi Liu, William P Tansey 145-184 minutes Abstract The oncoprotein transcription factor MYC is a major driver of malignancy and a highly validated but challenging target for the development of anticancer therapies. Novel strategies to inhibit MYC may come from understanding the co-factors it uses to drive pro-tumorigenic gene expression

Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study | Prostate Cancer and Prostatic Diseases nature.com Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study Mathias Winkler 16-20 minutes Abstract Introduction Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason </= 4 + 3 and stage </= T2c were 1–1 propensity score-matched for treatment year, age, PSA, Gleason, T-stage, cancer core length and use of neoadjuvant hormones. FT included 1–2 sessions. Primary outcom

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial | Journal of Clinical Oncology ascopubs.org Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial Umesh Mahantshetty 6-7 minutes PURPOSE We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. METHODS This phase III, single center, randomized controlled trial enrolled eligible patients undergoing radical radiotherapy for node-negative prostate adenocarcinoma, with estimated nodal risk ≥ 20%. Randomization was 1:1 to PORT (68 Gy/25# to pr

Cell‐cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone - Swanson - 2021 - The Prostate - Wiley Online Library onlinelibrary.wiley.com Cell‐cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone Gregory P. Swanson MD 28-36 minutes 1 INTRODUCTION The primary goal in the treatment of any cancer is the prevention of disease‐specific mortality (DSM). Metastatic disease is difficult to treat and usually incurable, resulting in DSM unless the patient dies of intercurrent disease or fatal accident. 1 - 4 Practically, cancer does not necessarily have to be totally eradicated by the primary intervention; rather the goal is to significantly delay progression to metastatic dis